Analysts Expect Seres Therapeutics Inc (NASDAQ:MCRB) Will Post Quarterly Sales of $6.82 Million

Wall Street analysts expect that Seres Therapeutics Inc (NASDAQ:MCRB) will report sales of $6.82 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Seres Therapeutics’ earnings. The highest sales estimate is $9.26 million and the lowest is $3.00 million. Seres Therapeutics posted sales of $10.63 million during the same quarter last year, which would indicate a negative year over year growth rate of 35.8%. The firm is expected to issue its next earnings results on Wednesday, March 4th.

On average, analysts expect that Seres Therapeutics will report full year sales of $34.03 million for the current fiscal year, with estimates ranging from $29.88 million to $36.14 million. For the next fiscal year, analysts expect that the business will report sales of $37.78 million, with estimates ranging from $18.70 million to $53.60 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow Seres Therapeutics.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.23) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.03. The business had revenue of $7.03 million during the quarter, compared to analysts’ expectations of $6.69 million.

Several equities analysts have commented on MCRB shares. HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of Seres Therapeutics in a research report on Thursday, November 21st. Chardan Capital reaffirmed a “buy” rating on shares of Seres Therapeutics in a research report on Thursday, September 19th. BidaskClub upgraded Seres Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 7th. Zacks Investment Research lowered Seres Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 29th. Finally, Cowen reissued a “buy” rating on shares of Seres Therapeutics in a research note on Monday, November 4th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Seres Therapeutics has a consensus rating of “Buy” and an average price target of $7.75.

A number of large investors have recently modified their holdings of MCRB. Squarepoint Ops LLC acquired a new stake in Seres Therapeutics in the third quarter valued at $215,000. Barclays PLC boosted its position in shares of Seres Therapeutics by 36.5% during the 3rd quarter. Barclays PLC now owns 19,737 shares of the biotechnology company’s stock worth $79,000 after acquiring an additional 5,278 shares in the last quarter. California State Teachers Retirement System boosted its position in shares of Seres Therapeutics by 72.3% during the 3rd quarter. California State Teachers Retirement System now owns 56,844 shares of the biotechnology company’s stock worth $228,000 after acquiring an additional 23,862 shares in the last quarter. State Street Corp increased its holdings in shares of Seres Therapeutics by 24.9% in the 3rd quarter. State Street Corp now owns 573,351 shares of the biotechnology company’s stock valued at $2,299,000 after acquiring an additional 114,375 shares during the last quarter. Finally, Voya Investment Management LLC increased its holdings in shares of Seres Therapeutics by 35.1% in the 3rd quarter. Voya Investment Management LLC now owns 13,670 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 3,555 shares during the last quarter. 91.91% of the stock is currently owned by hedge funds and other institutional investors.

Seres Therapeutics stock opened at $3.68 on Friday. The firm has a market cap of $276.55 million, a PE ratio of -1.51 and a beta of 1.82. Seres Therapeutics has a 52-week low of $2.02 and a 52-week high of $8.39. The company’s 50 day moving average is $3.69 and its two-hundred day moving average is $3.38.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).

Featured Story: What are the economic characteristics of a bear market?

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit